Earnings Releases·Nov 10, 2026, 4:05 PM ET

Braveheart Bio — Third Quarter 2026 Earnings Summary

**Financial Position & Liquidity:** Cash, equivalents, and investments surged to $503.5 million as of September 30, 2026, from $89.2 million at year-end 2025, driven by an August 2026 IPO raising ~$439.9 million; net loss narrowed to $26.5 million from $59.1 million in the prior year period.
**Operational Strategy:** R&D and G&A expenses rose to $30.1 million total for the quarter (from $59.3 million in 2025, excluding $58.8 million in prior-year IPR&D), while the company confirmed existing cash reserves will fund operations through 2029.
**Clinical Pipeline Progress:** Interim LIONHEART-HCM LVOT gradient data expected H2 2027; Hengrui Phase 3 (China) and nHCM Phase 2 extension topline results anticipated H1 2027; NOBLEHEART-HCM (nHCM) and TRUEHEART-HCM (U.S.) trials on track to initiate H1 2027.
**Product Data:** BHB-1893 demonstrated sustained efficacy in the oHCM open-label extension, with 90% of patients achieving LVOT gradient <30 mmHg and significant improvements in pVO2 and KCCQ-CSS scores over 52 weeks.